Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_1/mediawiki/images/9/98/New_stock.png': No such file or directory @ blob.c/OpenBlob/2480. convert: unable to open file `/home/wikinvest/src_live_1/mediawiki/images/9/98/New_stock.png' @ png.c/ReadPNGImage/2889. convert: missing an image filename `/home/wikinvest/src_live_1/mediawiki/images/thumb/9/98/New_stock.png/35px-New_stock.png' @ convert.c/ConvertImageCommand/2800.
|The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.|
Headquartered in Mumbai, India Lupin Limited is a transnational pharmaceutical company producing generic and branded formulations and Active Pharmaceutical Ingredients(APIs)The Company has secured global leadership position in Anti-TB and Cephalosporins and has a significant presence in the areas of Cardiovasculars (prils and statins), Diabetology, Asthma and NSAIDs(Non-steroidal anti-inflammatory drugs)
Lupin Limited BOD today(26/10/2010) announced in their office an increase in their working capital for the Q2,amounting to a profitability of Rs.350 Crore in the next month.The news is due to release in the market today around 3.00 pm.
Share holding pattern:
|Banks Fin. Inst. and Insurance||10.5%|
|Private Corporate Bodies||1.48%|
Lupin Limited BOD today(26/10/2010) announced in their office an increase in their working capital for the Q2,amounting to a profitability of Rs.350 Crore in the next month.The news is due to release in the market today around 3.00 pm.The BOD plans to raise the dividend,due to reinvestment by the old FII's and also planning to issue covertable debentures.
September 2011: Opportunities ahead in the US market, viz.: 1) Fortamet (US$85m): LUPN is FTF, has final approval & is evaluating launch options; 2) Femcon Fe (OC, US$65m): AG launch in Sep’11, post Teva’s exclusivity; 3) Geodon (US$800m): Shared FTF opportunity with 2 other players, Mar ’12 launch; 4) some OC approvals in 3Q/4Q.
The pharmaceutical industry is characterized by rapid advances in scientific knowledge and ability to discover new drugs.The industry is therefore led by large manufacturers and marketers of drugs investing heavily in research & development, having clinical testing, marketing and distributing capabilities.Some of the main competitors of Lupin are:
Comparison with the competitors:
|Financial metrics FY2008|
|Name||Yr Ended||Market Capitalization in Rs Cr||Sales Turnover in Rs Cr||Net Profit in Rs Cr|
|Sun Pharma||Mar '08||26,975.87||2,427.35||1,014.04|
|Dr Reddys Labs||Mar '08||9,662.53||3,428.40||475.22|
Market Share on the basis of Retail Sales Due to high level of fragmentation none of the Pharma Companies had more than 6% of the total market on the basis of the total retail sales.